Securities Snapshot

Our bi-monthly newsletter highlights important developments related to US civil and criminal securities law. 
The top half of a supreme court

Securities Snapshot is created by lawyers from our Securities Litigation & SEC Enforcement practice.

Read the Latest

Securities Snapshot for November 21, 2025

In This Issue: Southern District of New York Denies SEC’s Motion to Strike Affirmative Defenses of Former Cannabis Company CFO; Second Circuit Affirms Dismissal of Insider Trading Claims Against Nonfiduciary Financial Institutions; Ninth Circuit Affirms Class Certification in Securities Fraud Case Related to Zillow’s Algorithmic Pricing in the Real Estate Market; Third Circuit Affirms Dismissal of Securities Fraud Class Action Against Retailer Relating to Government Opioid Investigations; Northern District of California Grants Battery Maker’s Partial Judgment on Pleadings Based on ‘Full Context’ Analysis; Middle District of Tennessee Grants Plaintiffs Summary Judgment on Reliance in Securities Fraud Class Action Against Healthcare Company Relating to Purportedly Inaccurate Financial Projections; Middle District of Florida Allows Claims to Proceed Against Hertz for Allegedly Fraudulent Forecasts and Statements About Demand for Electronic Vehicles; Third Circuit Affirms Dismissal of Claims Against Cannabis REIT as Inactionable or Lacking Scienter Notwithstanding Tenant’s Fraud

Read more about these decisions and others in this month’s edition of Securities Snapshot.

Securities Snapshot for August 25, 2025

In This Issue: Fourth Circuit Affirms Dismissal of Putative Class Action; Ninth Circuit Partially Reverses Dismissal of Claims to Revive Lawsuit Against Avalara; Delaware Supreme Court Affirms Dismissal of Controlling Stockholder Claims Against AstraZeneca; District of Massachusetts Reaffirms the Principle That Legitimate Scientific Disagreement Does Not Give Rise to a Securities Fraud Claim; Northern District of Illinois Dismisses Putative Class Action Complaint Against Discover; District of Massachusetts Finds That the Plaintiffs’ Interpretation of FDA Guidance Does Not Give Rise to a Securities Fraud Claim

Read more about these decisions and others in this month’s edition of Securities Snapshot.